What is claimed is:

1. ~~A method of treating, preventing~~ Use of an interleukin-4 receptor (IL-4R) inhibitor in the manufacture of a medicament for treating or ameliorating at least one symptom or indication of eosinophilic esophagitis (EoE) ~~comprising administering a therapeutically effective amount of a pharmaceutical composition comprising an interleukin-4 receptor (IL-4R) inhibitor to a subject in need thereof.~~in

~~2. The method of claim 1, wherein the symptom or indication of EoE is selected from the group consisting of eosinophilic infiltration of the esophagus, thickening of the esophageal wall, food refusal, vomiting, abdominal pain, heartburn, regurgitation, dysphagia and food impaction.~~

~~3. The method of any one of claims 1 - 2, wherein the subject exhibits an allergic reaction to a food allergen contained in a food item selected from the group consisting of a dairy product, egg, wheat, soy, corn, fish, shellfish, peanut, a tree nut, beef, chicken, oat, barley, pork, green beans, apple and pineapple.~~

~~4. The method of any one of claims 1 - 2, wherein the subject exhibits an allergic reaction to a non-food allergen derived from one of dust, pollen, mold, plant, cat, dog or insect.~~

~~5. The method of any one of claims 1 - 4, wherein the administration of the IL-4R inhibitor results in reducing the level of an EoE-associated biomarker in the subject,~~

~~6. The method of claim 5, wherein the EoE-associated biomarker is selected from the group consisting of esophagus eosinophils, eotaxin-3, periostin, serum IgE (total and allergen-specific), IL-13, IL-5, serum thymus and activation regulated chemokine (TARC), thymic stromal lymphopoietin (TSLP), serum eosinophilic cationic protein (ECP), and eosinophil-derived neurotoxin (EDN).~~

~~7. A method of treating, preventing or ameliorating at least one symptom or indication of eosinophilic esophagitis (EoE) comprising:~~

~~selecting~~ a subject having ~~an allergic reaction to an allergen that renders the subject susceptible to EoE; and~~

~~administering a therapeutically effective amount of a pharmaceutical composition comprising an interleukin-4 receptor (IL-4R) inhibitor to the subject in need thereof.~~

~~8. The method of claim 7, wherein the allergen is a food allergen contained in a food item selected from the group consisting of a dairy product, egg, wheat, soy, corn, fish, shellfish,~~

peanut, a tree nut, beef, chicken, oat, barley, pork, green beans, apple and pineapple.a history of diagnosis.

9. The method of claim 7, wherein the allergen is a non-food allergen derived from one of dust, pollen, mold, plant, cat, dog or insect.

10. The method of any one of claims 7 - 9, wherein the symptom or indication of EoE is selected from the group consisting of eosinophilic infiltration of the esophagus, thickening of the esophageal wall, food refusal, vomiting, abdominal pain, heartburn, regurgitation, dysphagia and food impaction.

11. The method of any one of claims 7 - 10, wherein the administration of the IL-4R inhibitor results in reducing the level of an EoE-associated biomarker in the subject.

12. The method of claim 11, wherein the EoE-associated biomarker is selected from the group consisting of esophagus eosinophils, eotaxin-3, IgE, TARC, periostin, IL-5, IL-13, thymic stromal lymphopoietin (TSLP), and eosinophil-derived neurotoxin (EDN).

13. A method of treating, preventing or ameliorating at least one symptom or indication of eosinophilic esophagitis (EoE) comprising:

selecting a subject who exhibits at least one symptom or indication of EoE, wherein the subject has an elevated level of a biomarker selected from the group consisting of esophagus eosinophils, eotaxin-3, periostin, serum IgE (total and allergen-specific), IL-13, IL-5, TARC, TSLP, serum ECP, and EDN; and

administering a therapeutically effective amount of a pharmaceutical composition comprising an interleukin-4 receptor (IL-4R) inhibitor to the subject in need thereof.

14. The method of claim 13, wherein the subject is selected on the basis of exhibiting≥ 15 eosinophils per high powered field (hpf) in the esophagus prior to or at the time of the treatment ("baseline").from a esophageal biopsy specimen.

15. The method of claim 14, wherein the subject exhibits at least 50% decrease in the number of eosinophils per hpf from baseline at day 10 following the administration of the IL-4R inhibitor.

16. The method of claim 13, wherein the subject is selected on the basis of exhibiting an eotaxin-3 level of greater than about 50 pg/mL prior to or at the time of initiation of treatment ("baseline").

17. The method of claim 16, wherein the subject exhibits at least 50% decrease in eotaxin-3 level from baseline at day 10 following the administration.

18. The method of any one of claims 13 - 17, wherein the subject exhibits an allergic reaction to a food allergen is contained in a food item selected from the group consisting of a dairy

product, egg, wheat, soy, corn, fish, shellfish, peanut, a tree nut, beef, chicken, oat, barley, pork, green beans, apple and pineapple.

19. The method of any one of claims 13 - 17, wherein the subject exhibits an allergic reaction to a non-food allergen derived from a source selected from the group consisting of dust, pollen, mold, plant, cat, dog and insect.

20. The method of any one of claims 13 - 19, wherein the indication is selected from the group consisting of eosinophilic infiltration of the esophagus, thickening of the esophageal wall, food refusal, vomiting, abdominal pain, heartburn, regurgitation, dysphagia and food impaction.

21. A method of reducing the level of an eosinophilic esophagitis (EoE)-associated biomarker comprising administering a therapeutically effective amount of a pharmaceutical composition comprising an interleukin-4 receptor (IL-4R) inhibitor to a subject in need thereof.

22. The method of claim 21, wherein the EoE-associated biomarker is selected from the group consisting of the number of eosinophils in the esophagus, eotaxin-3, TARC, periostin, IgE, IL-5, IL-13, thymic stromal lymphopoietin (TSLP), and eosinophil-derived neurotoxin (EDN).

23. The method of claim 22, wherein the subject exhibits≥ 15 eosinophils per high powered field (hpf) in the esophagus prior to or at the time of the initiation of treatment ("baseline").

24. The method of claim 23, wherein the number of eosinophils in the esophagus is reduced by at least 50% from baseline by day 10 following administration of the IL-4R inhibitor.

25. The method of any one of claims 21 - 24, wherein the subject exhibits an allergic reaction to a food allergen contained in a food item selected from the group consisting a dairy product, egg, wheat, soy, corn, fish, shellfish, peanut, a tree nut, beef, chicken, oat, barley, pork, green beans, apple and pineapple.

26. The method of any one of claims 21 - 24, wherein the subject exhibits an allergic reaction to a non-food allergen derived from a source selected from one of dust, pollen, mold, plant, cat, dog, or insect.

27. The method of any one of claims 21 - 26, wherein the subject has eosinophilic esophagitis (EoE).

28. The method of any one of claims 1 - 27, wherein the subject, prior to or at the time of administration of the IL-4R inhibitor, has or is diagnosed with a disease or disorder selected from the group consisting of atopic dermatitis, asthma, allergic rhinitis and allergic conjunctivitis.

~~29. The method of any one of claims 1 - 28, wherein the IL-4R inhibitor is administered in combination with a second therapeutic agent or therapy, wherein the second therapeutic agent or therapy is selected from the group consisting of an IL-1 beta inhibitor, an IL-5 inhibitor, an IL-9 inhibitor, an IL-13 inhibitor, an IL-17 inhibitor, an IL-25 inhibitor, a TNFalpha inhibitor, an eotaxin-3 inhibitor, an IgE inhibitor, a prostaglandin D2 inhibitor, an immunosuppressant, a corticosteroid, a glucocorticoid, a proton pump inhibitor, a NSAID, allergen removal and diet management.~~

~~30. The method of any one of claims 1 - 29,~~ wherein the IL-4R inhibitor is an antibody or an antigen- binding fragment thereof that specifically binds interleukin-4 receptor alpha (IL-4Rα ~~and prevents the interaction of IL-4 and/or IL-13 with a type 1 or type 2 IL-4 receptor.~~

~~31. The method of claim 30 wherein the antibody or antigen-binding fragment thereof prevents the interaction of IL-4 and IL-13 with both type 1 and type 2 IL-4 receptors.~~

~~32. The method of claim 31,~~ wherein the antibody or antigen-binding fragment thereof comprises ~~the heavy chain complementarity determining regions (HCDRs) of a heavy chain variable region (HCVR)~~ a HCDR1 comprising the amino acid sequence of SEQ ID NO: ~~1 and the light chain complementarity determining regions (LCDRs) of a light chain variable region (LCVR)~~ 3, a HCDR2 comprising the amino acid sequence of SEQ ID NO: ~~2.~~
~~33. The method of claim 32, wherein the antibody or antigen-binding fragment thereof comprises three HCDRs (HCDR1 , HCDR2 and~~ 4, a HCDR3~~) and three LCDRs~~ (comprising the amino acid sequence of SEQ ID NO:5, a LCDR1 ~~, LCDR2 and LCDR3), wherein the HCDR1 comprises the amino acid sequence of SEQ ID NO: 3; the HCDR2 comprises~~ comprising the amino acid sequence of SEQ ID NO: ~~4; the HCDR3 comprises~~6, a LCDR2 comprising the amino acid sequence of SEQ ID NO: ~~5; the LCDR1 comprises~~ 7, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:8, and wherein the IL-4R inhibitor is formulated to be subcutaneously or intravenously administered to the subject.

2. The ~~use~~ of claim 1, wherein the subject:

(i) has a history of at least 2 episodes of dysphagia;

(ii) is inadequately responsive to treatment with a swallowed topical corticosteroid; and/or

(iii) is inadequately responsive to diet modification.

3. The use of any one of claims 1 – 2, wherein the subject has a concurrent disease or disorder selected from the group consisting of food allergy, atopic dermatitis, asthma, allergic rhinitis, allergic conjunctivitis and inherited connective tissue disorders.

4. The use of any one of claims 1 – 3, wherein the subject is an adult.

5. The use of any one of claims 1 – 4, wherein the subject to be treated:

has a serum IgE level of ≥ 150 kU/L; and/or
has a peripheral eosinophil count of ≥ 300 cells/μL.

6~~: the LCDR2~~. The use of any one of claims 1-5, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (HCVR) that comprises the amino acid sequence of SEQ ID NO: ~~7; and the LCDR3~~1 and a light chain variable region (LCVR) that comprises the amino acid sequence of SEQ ID NO: ~~8~~2.
~~34~~

7. The ~~method~~use of ~~claim 33~~any one of claims 1-6, wherein the ~~HCVR~~antibody or antigen-binding fragment thereof comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: ~~1~~13 and ~~the LCVR comprises~~a light chain comprising the amino acid sequence of SEQ ID NO: ~~2.~~14.
~~35~~

8. The ~~method of claim 30 or 31, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 13 and a light chain comprising the amino acid sequence of SEQ ID NO: 14.~~
~~36. The method~~use of any one of claims 1 ~~– 35~~-7, wherein the IL-4R inhibitor is dupilumab or a bioequivalent thereof.

9. The use of any one of claims 1-8, wherein the pharmaceutical composition or medicament is formulated to be subcutaneously administered.

10. The use of any one of claims 1-9, wherein each dose of the pharmaceutical composition or medicament comprises 50 – 600 mg of the antibody or antigen-binding fragment thereof.

11. The use of claim 10, wherein each dose comprises 300 mg of the antibody or antigen-binding fragment thereof.

12. The use of any one of claims 1-11, wherein the pharmaceutical composition or medicament is formulated to be administered once a week, once every two weeks, once every three weeks, or once a month.

13. The use of any one of claims 1-12, wherein the pharmaceutical composition or medicament is formulated to be administered at a dose of 300 mg of the antibody or antigen-binding fragment thereof once a week or once every two weeks.

14. The use of any one of claims 1-10, wherein the pharmaceutical composition or medicament is formulated to be administered at an initial dose followed by one or more subsequent doses, wherein each subsequent dose is administered to the subject one week or two weeks after the immediately preceding dose.

15. The use of claim 14, wherein the initial dose comprises 600 mg of the antibody or antigen-binding fragment thereof and each subsequent dose comprises 300 mg of the antibody or antigen-binding fragment thereof.

16. The use of claim 15, wherein:

each subsequent dose is administered to the subject one week after the immediately preceding dose; or

each subsequent dose is administered to the subject two weeks after the immediately preceding dose.

17. The use of any one of claims 1-16, wherein the pharmaceutical composition or medicament is contained in a syringe.

18. The use of any one of claims 1-16, wherein the pharmaceutical composition or medicament is contained in a pen delivery device.

19. The use of claim 18, wherein:

the pen delivery device is a reusable pen delivery device comprising a replaceable cartridge comprising the pharmaceutical composition or medicament; or

the pen delivery device is a disposable pen delivery device that is prefilled with the pharmaceutical composition or medicament.